The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
Open accessAbstract
The pharmacological interventions available for individuals in the early stages of psychosis are extremely limited. For those at clinical high risk for psychosis, there is no licensed treatment available. For those with first-episode psychosis, all licensed antipsychotic medications act via dopamine D 2 receptors. While treatment with antipsychotics is transformative in some patients, in others, it is ineffective. In addition, these medications can often cause adverse effects which make patients reluctant to take them. This is a particular problem in the early phases of psychosis, when patients are being treated for the first time, as unpleasant experiences may colour their future attitude towards treatment. Recent research has suggested that cannabidiol (CBD), a compound found in the Cannabis sativa plant, may have antipsychotic effects and relatively few adverse effects and could therefore be an ideal treatment for the early phases of psychosis, when minimising adverse effects is a clinical priority. In this review, we consider CBD’s potential as a treatment in the clinical high risk and first-episode stages of psychosis. First, we describe the limitations of existing treatments at these two stages. We then describe what is known of CBD’s mechanisms of action, effectiveness as a treatment for psychosis, adverse effects and acceptability to patients. We discuss how some of the outstanding issues about the utility of CBD in the early phases of psychosis may be resolved through ongoing clinical trials. Finally, we consider the impact of recreational cannabis use and over-the-counter cannabinoids preparations and discuss the potential therapeutic role of other compounds that modulate the endocannabinoid system in psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As a result, the early intervention and the clinical staging models have encouraged investigations into more benign pharmacological treatments including “neutraceuticals”, that is, food or food products with health and medical benefits, such as fish oil [109], N-acetylcysteine [110], and cannabidiol [111], that may be suitable for targeting emerging psychopathology.”
From Towards a youth mental health paradigm: a perspective and roadmap (2023) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568 · cited 2×
“Other ligands, such as palmitoylethanolamine, and effects of CBD on other receptors, such as GPR55 and TRPV1 (which are related to the endocannabinoid system), could also have a role, but the evidence supporting these is relatively sparse and is still limited to data from pre-clinical studies (Tzavara et al. 2006; Ryb…”
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039 · cited 2×
“CBD is a negative allosteric modulator of the receptors, limiting their response to their endogenous ligands: the endocannabinoids (Laprairie et al. 2015; Martínez-Pinilla et al. 2017).”
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., Pavón, F. J., Serrano, A. M., Selley, D. E., Parsons, L. H., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.129 · Cited by 934
Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use
Robinson, S. M., Sobell, L. C., Sobell, M. B., & Leo, G. I. (2014) · Psychology of Addictive Behaviors · doi:10.1037/a0030992 · Cited by 699 · cited 1×
“An alternative approach would be to permit the inclusion of recreational users but carefully monitor their exposure to cannabis throughout the trial via serial urine and blood testing, and self-report measures, such as the Timeline Followback (Robinson et al. 2014).”
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680
Self-citation
Research works printed but not linked: 3
- Gibbs B, Yates DA, Liebling J (2019) CBD in the UK. Centre for Medicinal Cannabis, London
- Morrison P, Taylor DM, Mcguire P (2019) The Maudsley guidelines on advanced prescribing in psychosis. John Wiley & Sons
- Taylor DM, Barnes TRE, Young AH (2018) The Maudsley prescribing guidelines in psychiatry–eleventh edition. John Wiley & Sons
Cited by
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 741
Self-citationTowards a youth mental health paradigm: a perspective and roadmap
Uhlhaas, P. J., Davey, C. G., Mehta, U. M., Shah, J., Torous, J., Allen, N. B., Avenevoli, S., Bella-Awusah, T., Chanen, A., Chen, E. Y. H., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02202-z · Cited by 318
Parkinson disease psychosis: from phenomenology to neurobiological mechanisms
Pagonabarraga, J., Bejr-Kasem, H., Martinez-Horta, S., & Kulisevsky, J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-023-00918-8 · Cited by 69
Matheson, J., Bourgault, Z., & Foll, B. L. (2022) · Biomolecules · doi:10.3390/biom12101462 · Cited by 41
Exploring causal mechanisms of psychosis risk
Oliver, D., Chesney, E., Cullen, A. E., Davies, C., Englund, A., Gifford, G., Kerins, S., Lalousis, P. A., Logeswaran, Y., Merritt, K., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105699 · Cited by 35
Self-citation
Metadata
- Authors
- Chesney, E., Oliver, D., & McGuire, P.
- Affiliations
- King's College London (GB)
- Corresponding author
- Chesney, Edward
- Venue
- Psychopharmacology
- Published
- 2021-07-13
- Volume
- 239
- Issue
- 5
- Pages
- 1179-1190
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC9110455
- OpenAlex
- W3179334404
- Cited by
- 40
- References
- 93
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 14 · 2023: 9 · 2022: 4 · 2021: 1
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- National Institute for Health and Care Research (NIHR300273)
- King's College London (MR/N013700/1)
- Medical Research Council (MR/N013700/1)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- cannabidiol, early psychosis, clinical high risk for psychosis, first-episode psychosis, antipsychotic drugs, antipsychotic adverse effects, endocannabinoid system, mechanism of action, treatment acceptability, recreational cannabis use, Cannabis sativa
- MeSH terms
- Cannabidiol, Cannabinoids, Cannabis, Humans, Psychotic Disorders, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabidiol (CBD) as a novel treatment in the early phases of psychosis. https://app.cochat.ai/papers/10.1007/s00213-021-05905-9
- The paper
- Chesney, E., Oliver, D., & McGuire, P. (2022). Cannabidiol (CBD) as a novel treatment in the early phases of psychosis. Psychopharmacology. https://doi.org/10.1007/s00213-021-05905-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.